按需口服替诺福韦/恩曲他滨预防：每位临床医生都需要了解的知识。
On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know.
机构信息
Division of Prevention Science, University of California, San Francisco, CA, USA.
Bridge HIV San Francisco Department of Public Health, San Francisco, CA, USA.
出版信息
J Gen Intern Med. 2020 Apr;35(4):1285-1288. doi: 10.1007/s11606-020-05651-2. Epub 2020 Jan 21.
Abstract
Based on the results of the IPERGAY study, on-demand HIV pre-exposure prophylaxis (PrEP; also known as "non-daily PrEP," "event-driven PrEP," or "2-1-1 PrEP") is being requested more frequently by patients who have intermittent sexual risk or are unable/unwilling to take daily PrEP; therefore, clinicians will be increasingly required to familiarize themselves with its appropriate use. In this perspective, we summarize data related to on-demand PrEP, describe advantages and disadvantages for this alternative dosing strategy, and provide clinical counseling points.
摘要
基于 IPERGAY 研究的结果，按需 HIV 暴露前预防（PrEP；也称为“非每日 PrEP”、“事件驱动 PrEP”或“2-1-1 PrEP”）越来越多地被那些有间歇性性风险或无法/不愿意服用每日 PrEP 的患者所要求；因此，临床医生将越来越需要熟悉其正确使用方法。在这一观点中，我们总结了与按需 PrEP 相关的数据，描述了这种替代给药策略的优缺点，并提供了临床咨询要点。
相似文献
1
On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know.
J Gen Intern Med. 2020 Apr;35(4):1285-1288. doi: 10.1007/s11606-020-05651-2. Epub 2020 Jan 21.
2
On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Lancet HIV. 2020 Feb;7(2):e113-e120. doi: 10.1016/S2352-3018(19)30341-8. Epub 2019 Nov 26.
3
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Lancet HIV. 2022 Aug;9(8):e554-e562. doi: 10.1016/S2352-3018(22)00133-3. Epub 2022 Jun 27.
4
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Lancet HIV. 2017 Sep;4(9):e402-e410. doi: 10.1016/S2352-3018(17)30089-9. Epub 2017 Jul 23.
5
Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
AIDS. 2018 Sep 24;32(15):2161-2169. doi: 10.1097/QAD.0000000000001939.
6
Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
PLoS Med. 2016 Sep 27;13(9):e1002132. doi: 10.1371/journal.pmed.1002132. eCollection 2016 Sep.
7
Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
AIDS Care. 2016;28 Suppl 1(sup1):48-55. doi: 10.1080/09540121.2016.1146653. Epub 2016 Feb 17.
8
First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
J Antimicrob Chemother. 2019 Sep 1;74(9):2752-2758. doi: 10.1093/jac/dkz220.
9
Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
Int J Infect Dis. 2020 May;94:41-43. doi: 10.1016/j.ijid.2020.03.014. Epub 2020 Mar 13.
10
Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
J Antimicrob Chemother. 2017 Feb;72(2):478-485. doi: 10.1093/jac/dkw412. Epub 2016 Sep 28.
引用本文的文献
1
National Trends in HIV Pre-Exposure Prophylaxis Dispensing to Young Adults, 2016-2023.
J Gen Intern Med. 2025 May 9. doi: 10.1007/s11606-025-09574-8.
2
Susceptibility to Lenacapavir Among Newly Diagnosed HIV-Positive Patients Followed Up in Mozambique That Presented With Primary Antiretroviral Resistance to Other Classes.
J Med Virol. 2025 Mar;97(3):e70317. doi: 10.1002/jmv.70317.
3
The Disparities of PrEP Adherence Among Men Who Have Sex With Men Between the Global South and the Global North: An Updated Determinantal Global Meta-Analysis.
J Acquir Immune Defic Syndr. 2025 May 1;99(1):1-8. doi: 10.1097/QAI.0000000000003635.
4
Evaluation of Hippocampal Microanatomy and Neuro-Biomarkers Following Administration of Silver Nanoparticles Conjugated with Tenofovir Disoproxil Fumarate in Experimental Diabetic Rats.
Pharmaceuticals (Basel). 2024 Dec 5;17(12):1635. doi: 10.3390/ph17121635.
5
Dynamicity of HIV Pre-exposure Prophylaxis Usage Pattern and Association with Executed Adherence in MSM: An Implementation Study in Hong Kong.
AIDS Behav. 2024 Apr;28(4):1327-1344. doi: 10.1007/s10461-023-04167-0. Epub 2023 Sep 29.
6
Pre-exposure prophylaxis service among men who have sex with men in Malaysia: findings from a discrete choice experiment.
Sci Rep. 2023 Aug 30;13(1):14200. doi: 10.1038/s41598-023-41264-5.
7
Delayed presentation of HIV among older individuals: a growing problem.
Lancet HIV. 2022 Apr;9(4):e269-e280. doi: 10.1016/S2352-3018(22)00003-0. Epub 2022 Feb 23.
8
Changes in Utilization of Birth Control and PrEP During COVID-19 in the USA: A Mixed-Method Analysis.
Arch Sex Behav. 2022 Jan;51(1):365-381. doi: 10.1007/s10508-021-02086-6. Epub 2021 Nov 8.
9
Facilitators and barriers of 2-1-1 HIV pre-exposure prophylaxis.
PLoS One. 2021 May 20;16(5):e0251917. doi: 10.1371/journal.pone.0251917. eCollection 2021.
10
PrEP Willingness and Adherence Self-Efficacy Among Men Who have Sex with Men with Recent Condomless Anal Sex in Urban China.
AIDS Behav. 2021 Nov;25(11):3482-3493. doi: 10.1007/s10461-021-03274-0. Epub 2021 May 1.
本文引用的文献
1
Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis - a qualitative analysis.
J Int AIDS Soc. 2019 Oct;22(10):e25389. doi: 10.1002/jia2.25389.
2
Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men - 20 Urban Areas, 2014 and 2017.
MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603. doi: 10.15585/mmwr.mm6827a1.
3
Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.
J Int AIDS Soc. 2019 Jul;22(7):e25338. doi: 10.1002/jia2.25338.
4
Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation.
Am J Mens Health. 2019 Jan-Feb;13(1):1557988319827396. doi: 10.1177/1557988319827396.
5
The Impact of Pre-Exposure Prophylaxis (PrEP) Use on Sexual Anxiety, Satisfaction, and Esteem Among Gay and Bisexual Men.
J Sex Res. 2019 Nov-Dec;56(9):1128-1135. doi: 10.1080/00224499.2019.1572064. Epub 2019 Feb 19.
6
HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016.
MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150. doi: 10.15585/mmwr.mm6741a3.
7
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.
JAMA. 2018 Jul 24;320(4):379-396. doi: 10.1001/jama.2018.8431.
8
HIV Preexposure Prophylaxis as a Gateway to Primary Care.
Am J Public Health. 2018 Oct;108(10):1418-1420. doi: 10.2105/AJPH.2018.304561. Epub 2018 Jul 19.
9
The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.
Ann Epidemiol. 2018 Dec;28(12):841-849. doi: 10.1016/j.annepidem.2018.06.005. Epub 2018 Jun 15.
10
The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the "participant"-physician relationship.
AIDS Care. 2018 Jun;30(sup2):41-47. doi: 10.1080/09540121.2018.1468013. Epub 2018 May 30.
Zotero 插件